rug-eluting stents (DESs) have been rapidly accepted in real world clinical practice by the interventional community, largely being used in percutaneous coronary interventions (PCI). 1 Previous randomized trials have reported that the first generation DESs, including sirolimus-eluting stents (SES; Cypher™) and paclitaxel-eluting stents (PES; Taxus™) reduced the incidence of restenosis and the need for revascularization over 6-12 months' follow-up compared with bare metal stents (BMSs). 2,3 Recent trials of DESs in acute myocardial infarction (AMI) have reported that DESs are superior to BMSs in reducing the need for repeat revascularization. [4] [5] [6] [7] However, DES implantation in the AMI setting is still known to be an important off-label indication and safety concerns regarding stent thrombosis (ST) and associated major adverse cardiac events (MACE) have been raised because of the systemic thrombotic milieu of the early period of AMI and the combined potentially increased thrombogenicity of the DES itself by causing delayed healing of the coronary endothelium compared with BMSs. [8] [9] [10] However, recently the KAMIR (Korea AMI Registry) study group reported that the use of DESs in Korean patients with AMI was clinically safe and effective. 11 There is very limited information regarding the angiographic and clinical outcomes among the different DESs in patients with AMI undergoing PCI, especially DESs other than SES and PES. Park et al showed that SES implantation in AMI patients was associated with a reduction of angiographic restenosis at 6 months compared with PES. 12 However, to our knowledge, there are few ongoing studies and no published data comparing SES, PES, and zotarolimus-eluting stents (ZES; Endeavor™) in AMI patients undergoing PCI, so this study was designed to investigate whether there are differences in safety and efficacy, specifically the 6-month angiographic and 1-year clinical outcomes, in patients with AMI undergoing PCI with these 3 different major early-generation DESs.
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Methods

Study Population and Study Purposes
PCI Procedure
Before DES implantation, patients were preloaded with 200 mg of aspirin, 300-600 mg of clopidogrel (Plavix ® , Bristol-Myers Squibb and Sanofi-Aventis) as a dual antiplatelet regimen. After DES implantation, 100 mg/day of aspirin was prescribed indefinitely and 75 mg/day clopidogrel was recommended for at least 12 months. In some selective patients who had a potentially higher risk of ST and repeat AMI, 200 mg of cilostazol (Pletaal ® , Otsuka Pharmaceutical Co, Ltd, Japan) was added as a 'triple antiplatelet regimen' and maintained with 100 mg twice daily for at least 30 days.
For the antithrombotic regimen, a 5,000-unit bolus of unfractionated heparin (UFH) was administered intravenously before PCI. At the beginning of the intervention, 50 U/kg was given after sheath insertion and supplemental doses were given to maintain an activated clotting time of 250-300 s. After the index PCI, 24,000 units of UFH/day was continuously infused for at least 2 days.
Stent implantation was performed according to standard clinical practice through either the femoral or radial approach. A Judkins 6 or 7 French large lumen guiding catheter and a 0.014-inch coronary guidewire were used. In the case of significant angiographically visible thrombi in the target lesion, repeat thrombus aspiration was performed using an aspiration catheter such as the Export ® XT Aspiration Catheter (Medtronic) or Thrombuster II catheter (thrombus extraction catheter, Kaneka Corp, Japan). Stents were mostly deployed after thrombus aspiration or predilation according to standard technique. Selection of SES or PES or ZES was according to the operator's discretion, but for the DES selection at the time of index PCI, it was strongly recommended to select in a random fashion regardless of lesion characteristics and clinical setting in order to reflect "real world" clinical practice. Adjuvant post-balloon dilatation was performed in selected patients to get optimal stent expansion. Intravascular ultrasound (IVUS) guided PCI was strongly recommended to get the optimal result.
Quantitative coronary angiography (QCA) was performed with an automated coronary analysis program (BH 3000; Philips, Best, The Netherlands) at baseline (angiography before index PCI) and immediately after stent deployment. The pre-and post-PCI minimal luminal diameter (MLD), the proximal, distal and mean reference vessel diameters (RVD), acute gain and percentage of restenosis before and immediately after stent implantation were measured. The acute gain was calculated as the difference between the post-and pre-PCI MLD.
Study Definitions
Binary restenosis was defined as >50% diameter stenosis. Percentage of restenosis was defined as the mean of the percent stenosis of the restenosis area in each group. The late loss was calculated as the difference between post-PCI MLD and follow-up MLD.
Total MACE were defined as death from any cause, Qwave MI, non Q-wave MI, target lesion revascularization (TLR) and target vessel revascularization (TVR). TLR-MACE was defined as cardiac death, Q-wave MI and TLR. Q-wave MI was defined as development of pathologic Q-waves in >2 contiguous leads with elevation of the postprocedural creatine kinase MB isoenzyme (CK-MB) level above the upper normal value. TLR was defined as repeat revascularization in the target lesion, including emergency or elective coronary artery bypass grafting (CABG) or repeat PCI. TVR was defined as repeat revascularization in the target vessel, including emergency or elective CABG or repeat PCI. Definite ST was defined as a filling defect suggestive of thrombus on angiography, and probable ST was defined as the AMI or sudden cardiac death attributable to the treated target lesion. ST was then classified by the Academic Research Consortium (ARC) definition as acute (<24 h), subacute (1-30 days), late (31-360 days), or very late (>360 days) from the index PCI. 13 Diabetes mellitus was defined as fasting blood glucose concentration ≥126 mg/dl or taking diabetes medications. Hypertension was defined as repeated measurements of ≥140 mmHg systolic blood pressure or ≥90 mmHg diastolic blood pressure or previous diagnosis of hypertension under antihypertensive medication. Smoking status was classified as non-smoker or smoker. Dyslipidemia was defined as meeting the following criteria: total cholesterol >200 mg/dl, triglycerides >150 mg/dl, highdensity lipoprotein-cholesterol <40 mg/dl, or low-density lipoprotein-cholesterol >100 mg/dl.
Angiographic and Clinical Follow-up: Study Endpoints
Angiographic follow-up was scheduled at 6 months after the index PCI. Angiographic parameters such as follow-up MLD, late loss, percentage of restenosis, restenosis type and binary restenosis were measured by repeat QCA. Complete cumulative clinical outcomes, including cardiac death, total death, Q-wave MI, non-Q wave MI, TLR, TVR and all-MACE, were assessed at 1 year after the index PCI.
Statistical Analysis
Continuous variables are presented as mean ± SD. Categorical variables are expressed as frequency (%). Comparisons of continuous variables among the 3 DES groups were performed with 1-way ANOVA analysis. Multiple comparisons test in ANOVA was done with Duncan's method. Comparisons of categorical variables among the 3 DES groups were performed with a Chi-square test or Fisher's exact test. To identify the predictors of binary restenosis in patients with AMI, multivariate logistic regression analysis was used. To identify the independent risk factors for late loss in patients with AMI, multivariate linear regression analysis was used. Univariate variables with P<0.20 were entered into the multivariate analysis. A P<0.05 was considered statistically significant. Statistical analysis was performed using the SPSS 10.0 software package (SPSS Inc, Chicago, IL, USA).
Results
Baseline Characteristics
A total of 355 consecutive AMI patients (116 patients in SES group, 153 patients in PES group, 86 patients in ZES group) were enrolled. Baseline clinical characteristics of the subjects were similar among the 3 groups except for sex ( Table 1) . Among the 38 patients meeting the exclusion criteria, 10 were implanted with a SES, 14 with a PES, and 7 with a ZES, and 6 died before PCI. There were more men in the ZES group than in the PES group. Procedural data for the subjects are presented in Table 2 . The number of total stents implanted in the PES group was greater compared with the SES and ZES groups, and this difference might have originated from the higher incidence of multiple stenting in the PES group. The implanted stent length was longer in the SES group than in the PES group but was similar to that in the ZES group ( Table 2) . 
Angiographic and Clinical Outcomes
The 6-month angiographic follow-up rate was 61.6%. At 6 months, the follow-up MLD was greater in the SES group than in the PES group, but not the ZES group ( Table 3) . The PES group had a higher trend of binary restenosis compared with the SES and ZES groups, and the mean percentage of restenosis in the PES group was higher than that of the SES group but similar to that of the ZES group. The SES group showed lower late loss compared with the PES and ZES groups. The mid-term angiographic outcomes of the ZES group, including follow-up MLD, percent restenosis and late loss, were similar with those for the PES group, except for the similar incidence of binary restenosis and greater late loss compared with the SES group ( Table 3) . However, there were no differences in the 1-month clinical outcomes, including in-hospital death, cardiac death, total death, and 1-year clinical outcomes, including death, MI, repeat PCI, and MACE, among the 3 groups. The inci- Table 4) .
Independent Risk Factors for Late Loss
Univariate linear regression analysis also revealed that the type of DES (PES vs SES: β 0.261, P=0.009) and the presence of an ostial lesion (β 0.316, P=0.008) were independent risk factors for late loss. Further, the total number of implanted stents tended to be an important predictor of late loss (β 0.150, P=0.072, Table 5 ). In the multiple linear regression analysis, after adjustment for the type of DES (PES vs SES), ostial lesion, and the total number of stents implanted, finally the type of DES (PES vs SES, β 0.233, P=0.022) and the presence of an ostial lesion (β 0.281, P=0.020) also remained as independent risk factors for late loss ( Table 5) .
Discussion
The main finding of the present study is that at 6 months, the use of a SES during primary PCI in patients with AMI was associated with a lower incidence of binary restenosis, lower percent restenosis, and lower late loss when compared with PES. The mid-term angiographic outcomes for ZES, including follow-up MLD, percent restenosis and late loss, were similar with the PES, except for the similar incidence of binary restenosis and greater late loss compared with the SES group. Further, the type of DES implanted (PES vs SES) and the presence of an ostial lesion were significantly associated with binary restenosis and were independent risk factors for late loss at 6 months. However, the overall incidence of ST and major clinical outcomes, including death, MI, repeat PCI and MACE, up to 6 months were not different among the 3 different DES groups, suggesting the angiographic benefit of the SES group shown at 6 months did not translate into more favorable clinical outcomes up to 1 year compared with the PES and ZES groups. We believe there were several good explanations for this result. First, it is well known that even in experienced centers with an acceptable door-to-balloon time delay, a significant proportion of subjects undergoing primary coronary angioplasty do not experience full myocardial reperfusion and so the extent of myocardial damage may be relevant. The subsequent mortality rate depends primarily on final infarct size and left ventricular dysfunction, as well as on the occurrence of the no-reflow phenomenon, factors that are all independent of the type of stent used. In the present study, no estimates of infarct size were provided. Secondly, even "angiographically" significant restenosis of the target vessel may not impair distal coronary blood flow to a reduced amount of viable myocardium and may not result in recurrent ischemia or symptoms in post-MI patients. However, we did not evaluate the amount of viable myocardium. Other factors such as infarct location and vessel size may obviously account for the discrepancy between lumen loss rate and clinical events. Thus, we consider it was hard to expect that after the reduced restenosis rate in the SES group, which had lower lumen loss compared with the PES and ZES groups, would translate into better clinical outcomes.
A number of randomized comparative studies of SES and PES have been performed and have reported that the SES is superior to the PES in certain clinical groups. 14-17 Tables 1,4 .
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Although there were no differences between SES and PES in the MACE-free survival and rate of re-intervention for restenosis at 1-year follow-up in patients with AMI, Hofma et al showed that a trend toward a worse outcome was seen in the patients treated with a PES compared with those with a SES. 15 In South Korea, recent studies also showed that DES implantation in patients with AMI was clinically safe and that SES implantation in AMI patients was associated with a reduction of angiographic restenosis at 6 months compared with PES. 11, 12 However, there are few studies comparing SES, PES, and ZES in AMI patients. In the present study, the mid-term angiographic outcomes of ZES appeared similar to those for PES (similar follow-up MLD, percent restenosis and late loss), except for the similar incidence of binary restenosis and greater late loss when compared with the SES group ( Table 3) . To the best of our knowledge, this study was unusual in comparing the clinical and angiographic outcomes of AMI patients undergoing PCI with 3 major DESs. Although data for SES and PES implantation in the infarct-related vessels has been published, those for ZES in AMI treatment are scarce. The main value of the present report is that, on the scale of approximately 100 patients each, we have shown that the ZES is as safe and effective for AMI as SES and PES. In 3 previous randomized studies, angiographic restenosis was significantly lower with SES compared with PES, [18] [19] [20] and there are several possible reasons for this difference: (1) differences in the pharmacological action of sirolimus and paclitaxel, (2) drug-release kinetics, (3) the pattern of drug distribution in the arterial wall, and (4) stent characteristics. 21 Many investigators have suggested that several factors influence the higher risk of restenosis after DES implantation. A previous study showed that predictive factors of restenosis after PCI with SES or PES in patients presenting with symptomatic coronary artery disease were vessel size, final diameter stenosis, and DES type (PES). 22 The RVD of the treated vessel has been regarded as an important predictor of restenosis. 23, 24 In our study, the subgroup of vessels with a RVD ≥2.75 mm showed no difference in angiographic restenosis compared with the subgroup with a RVD <2.75 mm, which suggests that factors other than vessel size play a role in predicting restenosis in AMI patients.
Coronary bifurcations are at high risk of developing restenosis because of their constant exposure to turbulent blood flow. 25 However, in practice, coronary bifurcations are a predictor of restenosis with BMSs, but not always with DESs. 26 In our study, coronary bifurcation was not a predictor of restenosis, which supports that coronary bifurcation may not be a predictor of restenosis in the DES era.
In the present study, we found that the type of DES implanted and the presence of an ostial lesion were independent predictors of binary restenosis and late loss. The use of PES in the setting of AMI was significantly associated with a higher incidence of binary restenosis compared with SES ( Table 4 ) and was an independent risk factor for late loss compared with SES (Table 5) . Therefore, detailed and careful revascularization of an ostial lesion in the AMI setting should be emphasized to achieve optimal angiographic results. However, this mid-term angiographic difference among the 3 major DESs did not affect the incidence of ST and clinical outcomes for up to at least 1 year, suggesting longer clinical follow up with a larger study population with suitable randomization is warranted to obtain the final conclusion.
Study Limitations
First, this study was a retrospective analysis using prospective registry data and the cohort included patients not randomly assigned to a given DES type. Second, we analyzed only up to the 1-year clinical outcome and did not investigate the long-term outcomes among the 3 different DES groups. Third, this study lacks the comparative power of specifically designed trials of the relative merits of SES, PES and ZES. Fourth, there were limited cases of IVUS-guided PCI at the time of AMI presentation, which may possibly negatively affect the long-term outcomes. Fifth, this study had a selection bias against high-risk AMI patients. We excluded patients with cardiogenic shock, multivessel coronary intervention or renal insufficiency, so the subjects enrolled in the study should be regarded as relatively low-risk AMI patients compared with the variety of AMI patients in "real world" clinical practice. Sixth, because the 6-month angiographic follow-up rate was relatively low (61.6%), our assessment of the effect of the 3 different major DESs on reducing restenosis could be relatively obscured to give a strong angiographic conclusion. However, in fact, to compensate for the limited angiographic follow-up rate, our intention was to get perfect clinical follow-up data up to 1 year and this was feasible and possible. Because most of the study population lived near the hospital and South Korea is a relatively small country, we could get complete clinical follow-up data either from the patient's office visits or by telephone contact. Seventh, a total of 355 patients is not enough to detect slight differences in the clinical outcomes among 3 types of DES. For example, all-MACE at 1-year was 7.2% in PES and 4.7% in ZES, which is insignificant on this scale. If a large number of patients was enrolled to evaluate different DESs, this difference could reach significance. Finally, because the study population was patients after AMI, we think that the remaining cardiac function is a more important regulating factor for evaluating prognosis than the percent restenosis of the infarcted artery. However, as shown in Table 1 , the peak level of CK-MB did not differ among the 3 types of DES, and it has been reported that in patients with AMI the peak level CK-MB is associated with prognosis and the extent of injury to the myocardium. 27 Therefore, we analyzed the data on the assumption that the remaining cardiac function at follow-up would be little different, although we did not perform follow-up echocardiography.
It should be kept in mind that this study reflects the practical mid-term angiographic and 1-year clinical outcomes of real world clinical practice in a series of Asian AMI patients undergoing PCI with 3 different major DESs.
Conclusion
The SES implantation in AMI patients undergoing PCI might be associated with a significant reduction of angiographic restenosis and late loss at 6 months compared with PES and ZES. However, these angiographic benefits may not translate into better clinical outcomes in real world clinical practice up to 1 year. Further large, randomized controlled studies with long-term follow-up comparing the efficacy and safety of the 3 major different DESs in AMI patients undergoing PCI are needed to get the final conclusion.
